[Adjuvant surgery for advanced gastric cancer].
OBJECTIVE
The purpose of this study was to evaluate the efficacy of(adjuvant)surgery following the response to chemotherapy for advanced gastric cancer.


METHODS
The subjects were 20 advanced gastric cancer patients who had undergone gastrectomy following the response to combination chemotherapy with docetaxel and S-1 from September 2003 to December 2008. They consisted of 14 men and 6 women, with a median age of 58. 8, who received combination chemotherapy with docetaxel and S-1 according to the following regimen: S-1, 80 mg/m2, was administered on 14 consecutive days followed by a 7-day rest period, and docetaxel, 40 mg/m2, was administered on day 1.


RESULTS
The average treatment was 4. 4 courses. They consisted of 17 PR and 3 SD. The median overall survival was 855 days. 2-year and 3-year survival was seen in 80% and 54. 9% of patients, respectively, following macroscopically curative operation. Median survival of patients with liver metastasis and peritoneal dissemination was 865 days and 510 days, respectively.


CONCLUSIONS
Adjuvant surgery might be effective in advanced gastric cancer patients except for cases of peritoneal dissemination.
Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.
Junya
J
Taomoto
Kazuaki
K
Tanabe
Takahisa
T
Suzuki
Yoichi
Y
Hamai
Manabu
M
Emi
Jun
J
Hihara
Kazuhiro
K
Yoshida
Morihito
M
Okada
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid